PharmaFocus Today – Page 60 – media

“Generic name” circulation breaks the dilemma of purchasing medicines. Shenzhen Medical Insurance launches new “dual channel” drug regulations

“The drug name on the hospital’s external prescription is the same as the drug in the pharmacy, why can’t I buy it?” “Why can’t the community health center issue an external prescription, and I have to go to the hospital?” Recently, the Shenzhen Medical Insurance Bureau launched a new “dual channel” drug management regulation, taking the lead in the province to upgrade the circulation of external prescriptions from “trade name” to “generic name”, and launched the community health external prescription circulation service. These problems that once troubled the general public are being solved. “Dual channel” drugs refer to national medical insurance negotiated drugs with high clinical value, urgent need for patients, and low substitutability. There are currently more than 600 kinds in Shenzhen. In order to ensure the patient’s drug needs, when such drugs are not available in the hospital, they can be purchased at the pharmacy through external prescriptions, ...
- Source: drugdu
- 224
- March 11, 2025
The company exported a batch of PPR vaccines to Mongolia a few years ago, and currently has no other overseas sales cases

Tiankang Bio said on the investor interaction platform on March 10 that the company had exported a batch of PPR vaccines to Mongolia a few years ago, and currently has no other overseas sales cases. In the future, the company will continue to pay attention to international market demand, actively evaluate and explore qualified vaccine product export opportunities, and expand its overseas business layout. https://finance.eastmoney.com/a/202503103341125095.html
- Source: drugdu
- 153
- March 11, 2025
Will not transfer main business or inject assets to Tiankang Pharmaceutical

On March 6, Tiankang Bio said on the investor interaction platform that the company currently has no plan to transfer its main business to Tiankang Pharmaceutical, nor does it have any plan to inject assets into Tiankang Pharmaceutical. In December 2024, Tiankang Bio announced that its holding subsidiary Tiankang Pharmaceutical intends to apply for a public offering of shares to unspecified qualified investors and list on the Beijing Stock Exchange. Tiankang Bio believes that this move will help further enhance Tiankang Pharmaceutical’s production capacity and R&D and innovation capabilities, promote business development, and improve its governance level and industry competitiveness. After the completion of this public offering, Tiankang Bio will still be the controlling shareholder of Tiankang Pharmaceutical, and both the company and Tiankang Pharmaceutical will be able to continue to maintain independence and sustainable operating capabilities. Recently, an investor asked on the interactive platform whether Tiankang Pharmaceutical will transfer ...
- Source: drugdu
- 144
- March 10, 2025
The first tumor vaccine is expected to be launched in 2027 to treat this cancer

On March 5, local time, American vaccine manufacturer Moderna said at an investor conference that the company is expected to launch its first tumor vaccine in 2027. At the close of the day, Moderna’s stock price rose nearly 16%. Moderna is developing a personalized tumor vaccine with Merck and has conducted late-stage clinical trials on patients with severe skin cancer (melanoma). Stephen Hoge, president of Moderna, said at an investor conference on Wednesday that the first tumor vaccine may have the opportunity to bring “considerable revenue” to the company. Moderna released interim research data on the vaccine as early as the end of 2023, showing that the possibility of death or cancer recurrence in melanoma patients treated with this vaccine and Merck’s cancer therapy Keytruda was reduced by half. This tumor vaccine is based on Moderna’s mRNA technology. Previously, mRNA COVID-19 vaccines have proven that they can activate the body’s ...
- Source: drugdu
- 212
- March 10, 2025
Another pharmaceutical company changes ownership

The entry of Shaoguan Gaoteng has brought new opportunities to Chengda Bio, but whether it can break through still needs time to test. Recently, Chengda Bio issued an announcement stating that the Liaoning Provincial State-owned Assets Supervision and Administration Commission officially withdrew and the company changed to a “no actual controller” status. The change began with the reorganization of the board of directors of its controlling shareholder Liaoning Chengda. Shaoguan Gaoteng took control of Liaoning Chengda by nominating four non-independent directors (more than half of the seats), and indirectly held 54.67% of Chengda Bio’s shares. Shaoguan Gaoteng is a wholly-owned subsidiary of Guangdong Private Investment Co., Ltd. (Guangdong Private Investment), which was established by the Guangdong Provincial Government and focuses on strategic areas such as new energy and life sciences. In 2019, Guangdong Private Investment increased its holdings in Liaoning Chengda through Shaoguan Gaoteng, and became the largest shareholder with ...
- Source: drugdu
- 127
- March 10, 2025
Sinclair Xinkeli Aesthetic Medical Multifunctional Operation Platform V30 Registration Application Accepted

On March 5, 2025, Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary Viora Ltd. (hereinafter referred to as “Viora”) received the “Acceptance Notice” issued by the National Medical Products Administration (NMPA), and its application for registration of the Class III medical device optical radiofrequency therapy device V30 was accepted. It is reported that Viora, an energy source medical beauty device company, was acquired 100% of its equity by Sinclair, a wholly-owned subsidiary of Huadong Medicine in the UK, in February 2022. This time, the acceptance of Sinclair’s Xinkeli Aesthetics all-round skin medical beauty product V30 registration application is another major progress in the field of medical beauty energy source equipment. Huadong Medicine continues to expand its minimally invasive + non-invasive medical beauty map, realizes the layout of the entire industry chain on a global scale, continuously enhances its comprehensive strength in the medical beauty sector, and gradually advances to the ...
- Source: drugdu
- 222
- March 10, 2025
Focusing on critical illness, Mindray Biotech and Likang Biomedical have reached a strategic cooperation

The reporter learned from Mindray Biotech that Mindray Biotech and Likang Biomedical Technology Holdings Co., Ltd. recently officially signed a strategic cooperation agreement. This strategic cooperation focuses on blood gas products and focuses on the field of critical and emergency diseases for adults and neonates. It is the advantage of Wuhan Mindray and Likang Biotech in forming strategic synergy and resource complementarity in three aspects: expert guidance, benchmark demonstration and market expansion. Innovate instant diagnosis and lead smart medical care. https://finance.eastmoney.com/a/202503043335621969.html
- Source: drugdu
- 115
- March 7, 2025
Zhao Jing, Vice Chairman of Buchang Pharmaceutical, made suggestions on AI empowering traditional Chinese medicine at the two sessions

During the 2025 National People’s Congress, Zhao Jing, deputy to the National People’s Congress and vice chairman of Buchang Pharmaceutical (603858), made suggestions on “AI empowering the inheritance and innovation of traditional Chinese medicine” and proposed solutions for the modernization of traditional Chinese medicine from the aspects of policy planning, technology integration, and industrial upgrading. Zhao Jing suggested that by establishing a standard system for traditional Chinese medicine data to standardize traditional Chinese medicine terminology, promote cross-domain data sharing, formulate a strategy for the integration of AI and traditional Chinese medicine, and clarify demonstration projects for application scenarios such as intelligent diagnosis and telemedicine. In the field of intelligent manufacturing, she proposed the use of AI technology to transform production links, including precise control of temperature and humidity, screening of Chinese herbal medicine ingredients, and the construction of a full-process quality traceability system. She suggested that the government should issue ...
- Source: drugdu
- 130
- March 7, 2025
It is recommended to optimize the review and approval mechanism of biomedicine in Chengdu and Chongqing, and further promote the collection of non-immunization program vaccines

Jiang Lingfeng, deputy to the National People’s Congress and vice chairman and president of Zhifei Bio, submitted several suggestions on the biomedicine industry at this National People’s Congress. Among them, in order to “promote the high-quality development of the biomedicine industry in the Chengdu-Chongqing Twin Cities Economic Circle”, Jiang Lingfeng suggested optimizing the review and approval mechanism of biomedicine in Chengdu and Chongqing, increasing policy support, and at the same time, providing more support in talent cultivation and introduction, and innovation resource allocation. In order to “further promote the collection of non-immunization program vaccines and promote the healthy and sustainable development of the vaccine industry”, Jiang Lingfeng suggested resolving historical arrears through special debts, optimizing the disease control payment system, and building a new “special fund direct payment” mechanism to effectively alleviate the financial pressure of enterprises. https://finance.eastmoney.com/a/202503053337321863.html
- Source: drugdu
- 182
- March 7, 2025
It is recommended to optimize the construction of the centralized procurement system for biopharmaceuticals and support the high-quality development of enterprises

In recent years, the development of the biopharmaceutical industry has been in full swing. Policy support, capital influx and technological innovation have formed a synergy to promote the industry into a period of rapid growth. Ankang, deputy to the National People’s Congress and chairman of Hualan Bio, an important domestic leader in the field of blood products, vaccines and monoclonal antibodies, proposed during the two sessions of the National People’s Congress that it is recommended to optimize the construction of the centralized procurement system for biopharmaceuticals and support the high-quality development of biopharmaceutical companies. Recently, An Kang, deputy to the National People’s Congress and chairman of Hualan Bio, said in an interview with Cailianshe reporters: “General Secretary Xi Jinping attended the private enterprise symposium and delivered an important speech, emphasizing that the development prospects of the private economy in the new era and new journey are broad and promising, and ...
- Source: drugdu
- 149
- March 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.